Oxalobacter Formigenes for Kidney Stones
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests whether a harmless bacterium, Oxalobacter formigenes, can settle in the gut and influence the amount of oxalate—a natural chemical that can form kidney stones—in the urine of healthy individuals. Researchers aim to determine if the presence of this bacterium can help manage urinary oxalate levels, potentially reducing the risk of kidney stones. The trial seeks participants who are in good health and do not already carry this bacterium. As an unphased trial, it offers a unique opportunity to contribute to scientific understanding and potentially benefit future kidney stone prevention strategies.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It is best to discuss this with the trial coordinators.
What prior data suggests that Oxalobacter formigenes is safe for human consumption?
Research shows that Oxalobacter formigenes is safe for humans. Studies have found that this bacterium can live in the gut without causing harm and naturally exists in some people's digestive systems. Previous research has shown that it can settle in the gut and lower oxalate levels in urine, reducing the risk of kidney stones. Although specific safety data from these studies is lacking, the use of a naturally occurring bacterium suggests it should be well-tolerated.12345
Why are researchers excited about this trial?
Most treatments for kidney stones focus on pain management, stone removal, or reducing stone formation through medication and dietary changes. But Oxalobacter formigenes works differently, targeting the root cause by using a naturally occurring bacterium to break down oxalate in the gut before it can form stones. Researchers are excited about this approach because it could reduce oxalate levels without relying on medications that might have side effects. This method of colonization with beneficial bacteria offers a novel way to address kidney stones at their source, potentially providing a more natural and sustainable solution.
What evidence suggests that Oxalobacter formigenes might be an effective treatment for kidney stones?
Research has shown that Oxalobacter formigenes, a harmless type of bacteria, might help lower the risk of developing kidney stones made of calcium oxalate. One study found that people with this bacterium in their gut had a 70% lower chance of experiencing recurrent kidney stones. Another study demonstrated that the presence of this bacterium in the gut can reduce the risk of kidney stones returning. People who frequently develop kidney stones typically have less of this bacterium compared to those who do not, suggesting that its presence might offer protection against kidney stones. This trial will investigate the effects of colonizing participants with Oxalobacter formigenes to manage the risk of kidney stones.12367
Who Is on the Research Team?
John Knight
Principal Investigator
University of Alabama at Birmingham
Are You a Good Fit for This Trial?
This trial is for healthy individuals who are not currently colonized with the bacterium O. formigenes and have no history of liver, kidney, bowel or endocrine diseases that could affect ion absorption or urinary excretion.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dietary Control
Participants follow a controlled diet to establish baseline oxalate values and prepare for colonization
Colonization and Monitoring
Participants are colonized with Oxalobacter formigenes and monitored for changes in urinary oxalate
Follow-up
Participants are monitored for sustainability of colonization and changes in oxalate excretion
What Are the Treatments Tested in This Trial?
Interventions
- Oxalobacter formigenes
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Alabama at Birmingham
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Collaborator